Eboli

Researchers are conducting an observational, prospective, multicenter study in Italian cardiology centers to evaluate how well patients with Heart Failure with Reduced Ejection Fraction (HFrEF) follow guideline-recommended treatments. The study also aims to assess the safety of these treatments, monitor treatment patterns in patients with acute heart failure, and observe treatment approaches in all chronic heart failure patients regardless of their ejection fraction levels. The study involves two phases of educational interventions and data collection. Initially, healthcare providers will receive education on guideline recommendations and treatment patterns, followed by 3 months of patient data collection or up to 30 consecutive patients with chronic or acute heart failure. After 6 months, treatment modifications and outcomes will be evaluated. Then, a second educational session will highlight gaps between guidelines and practice, followed by another 3 months of data collection. Patients will be followed for 12 months total, with ongoing monitoring of treatment changes and outcomes. Participants will be assessed at enrollment and during the follow-up periods through clinical evaluations and data collection on treatment adherence and safety. The main outcome measured is adherence to guideline-directed medical therapies over 6 months. The study includes evaluations at 6 and 12 months after enrollment, with close monitoring of treatment patterns and patient health status throughout the study duration.

Researchers are evaluating patients who have experienced athero-thrombotic events such as coronary artery disease, cerebrovascular disease, or peripheral artery disease. The study aims to assess how well patients follow guideline recommendations, particularly focusing on improving cholesterol levels and other modifiable risk factors to reduce the chance of cardiovascular event recurrence. This observational and prospective study takes place across multiple cardiology centers in Italy to represent a broad patient population. The study includes several phases starting with an educational intervention to discuss guideline recommendations for secondary prevention. Following this, data is collected for three months or until 30 patients with documented cardiovascular conditions are enrolled, using a web-based case record form that identifies when guidelines are not followed and records reasons for non-adherence. After six months, primary and secondary outcomes are evaluated. A second educational intervention then shares findings from the first phase to highlight gaps in clinical practice, followed by another three-month data collection period and a further six-month outcome assessment. Finally, all patients are followed for 12 months to monitor longer-term results. Participants provide informed consent and are monitored through data collection forms that track adherence to guidelines and clinical outcomes. The main outcome measured is adherence to cholesterol management guidelines over six months. Additional assessments include adherence to recommendations for other cardiovascular risk factors. Throughout the study, researchers gather data to understand how guideline adherence affects patient health and to identify barriers to following best practices, with continuous follow-up over a year to evaluate sustained effects.

Researchers are evaluating the adherence, persistence, and effectiveness of treatment with PCSK9 inhibitors in people with hypercholesterolemia within a real-life Italian population. The study focuses on how well patients follow their treatment plans and how effective the medications are in managing their condition over time. The treatments being studied include the drugs Repatha (evolocumab) and Praluent (alirocumab), both administered by injection. The study collects data on these treatments as they are used in routine clinical practice without additional intervention from researchers. Participants will be monitored every six months to assess how consistently they use their PCSK9 inhibitor treatment, how long they continue the treatment, and how well the treatment controls their cholesterol levels. These evaluations will help understand the real-world use and impact of these medications in Italy.

Researchers are collecting and evaluating long-term data on clinical and radiographic outcomes to better understand the safety and performance of shoulder arthroplasty over time. This study includes people with various shoulder conditions such as osteoarthritis, osteonecrosis, rotator cuff tears, rheumatoid arthritis, fractures, and infections. The trial will follow participants for at least 10 years, with no early limit on follow-up duration. The study includes patients who are either scheduled for shoulder arthroplasty or have already undergone the procedure. Participants must be skeletally mature and expected to survive at least two years beyond surgery. The study is open-label and multi-center, involving both retrospective and prospective data collection. There are no specific interventions or treatments being compared, as the focus is on observing outcomes after shoulder arthroplasty. Participants will undergo assessments including clinical and radiographic evaluations at an average of once per year throughout the study. Outcome measures include the Constant score, ASES (American Shoulder and Elbow Surgeons) score, Oxford Score (optional in the UK), TESS, and MSTS scores related to pre-operative conditions. Researchers will monitor participants for safety and implant performance during the long-term follow-up, which can last a minimum of 10 years.